Moderna mRNA-4157 Phase 2 Trial Results 2023 Melanoma

Phase 2 clinical trial results for mRNA-4157 (V940), an individualized neoantigen therapy developed by Moderna and Merck for high-risk stage III/IV melanoma. The study evaluates distant metastasis-free survival in patients receiving adjuvant immune checkpoint inhibitor therapy combined with the investigational mRNA vaccine.